Indivior Pharmaceuticals (INDV) Enterprise Value (2021 - 2026)

Indivior Pharmaceuticals' Enterprise Value history runs 6 years deep, the most recent figure standing at -$175.0 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 53.08% year-over-year to -$175.0 million; the TTM figure through Mar 2026 stood at -$175.0 million (up 53.08% YoY), while the FY2025 annual figure was -$195.0 million, up 39.06% from the prior year.
• Enterprise Value was -$175.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$195.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$175.0 million in Q1 2026 to a low of -$893.0 million in Q4 2022.
• Historically, Enterprise Value has averaged -$455.2 million across 5 years, with a median of -$409.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value increased 18.14% in 2023, then jumped 56.22% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$893.0 million in 2022, then climbed by 18.14% to -$731.0 million in 2023, then surged by 56.22% to -$320.0 million in 2024, then surged by 39.06% to -$195.0 million in 2025, then advanced by 10.26% to -$175.0 million in 2026.
• The last three Enterprise Value figures came in at -$175.0 million (Q1 2026), -$195.0 million (Q4 2025), and -$445.0 million (Q3 2025), per Business Quant data.